All In Biotech

Drug Trial Radar · NCT06905522

A PAN-USR TB Multi-Center Trial

A Pan-Ultrashort Regimen for Drug-susceptible and Drug-resistant Pulmonary Tuberculosis: A Multi-Center Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 610 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

610

Planned (sponsor's estimate)

Start

Jun 18, 2025

Primary completion

Jan 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Shenzhen Third People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
First Affiliated Hospital of Zhejiang University; Beijing Chest Hospital, Capital Medical University; Shenyang Tenth People's Hospital; The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region; The Fourth Hospital of Inner Mongolia Autonomous Region; Guizhou Aerospace Hospital
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-TB is an innovative concept in TB treatment, aiming to develop a universal regimen effective for all forms of active TB, including both drug-susceptible and drug-resistant strains. The primary goal of the PAN-TB regimen is to simplify the treatment process, reduce costs, and improve treatment success rates. The ideal Target Regimen Profile (TRP) for PAN-TB includes superior efficacy compared to standard treatment for non-drug-resistant TB, a reduced treatment duration from the current 4-6 months to 2-3 months, and improved safety and tolerability. This project aims to explore a new ultra-short-course treatment regimen for both drug-sensitive (DS-TB) and drug-resistant TB (MDR/RR-TB), which aligns with the latest trends in TB treatment both domestically and internationally. The regimen also has significant practical implications for enhancing treatment efficacy and reducing patient burden. Furthermore, the study will explore the identification of new biomarkers closely linked to treatment outcomes over the course of full-cycle therapy.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • Bedaquiline (B)Drug

    The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.

  • Sitafloxacin (S)Drug

    200mg once daily

  • Linezolid (L)Drug

    600mg once daily

  • Pyrazinamide (Z)Drug

    20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.

  • Isoniazid (H)Drug

    4-6 mg/kg once daily, 300 mg once daily

  • Rifampicin (R)Drug

    8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.

  • Ethambutol (E)Drug

    15-25 mg/kg once daily, 750 mg once daily

  • Moxifloxacin (M)Drug

    400mg once daily

  • Pretomanid (Pa)Drug

    200mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unfavorable outcomesTime frame: 12 months (52 weeks)
  2. SafetyTime frame: 2 months (9 weeks)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chest Hospital of Capital Medical University

    Beijing, China · Recruiting

  • Shenzhen Third People's Hospital

    Shenzhen, China · Recruiting

  • The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region

    Ürümqi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.